Literature DB >> 23390981

Brain-derived protein concentrations in the cerebrospinal fluid: contribution of trauma resulting from ventricular drain insertion.

Sebastian Brandner1, Christian Thaler, Michael Buchfelder, Andrea Kleindienst.   

Abstract

In recent years, the measurement of biomarkers following neurotrauma assisted in improving outcome prediction and guiding therapy. The use of neuroproteins as diagnostic parameters requires a detailed knowledge of their dynamics in biological fluids for an appropriate interpretation. S100B is the most widely studied neuromarker, and its concentration in serum and cerebrospinal fluid (CSF) reflects the extent of brain damage. Neuron-specific enolase (NSE) is considered reflecting neuronal damage, while Beta-Trace is a lepto-meningeal protein used to diagnose CSF leakage. In five patients treated with an external ventricular drain (EVD) because of aneurysmal subarachnoid hemorrhage (SAH, n=3) or postinfectious hydrocephalus (n=2), an EVD exchange was performed 8 to 12 days after initial insertion. S100B and NSE were measured with the Cobas e411(®) electrochemiluminescence assay (Roche Diagnostics, Mannheim, Germany) and Beta-Trace with the BN Pro Spec(®) nephelometer (Dade Behring/Siemens, Germany) 1 h before EVD exchange, upon the insertion of the new drain, and 1, 3, 6, 12, 18, 24 and 48 h after EVD exchange. Before EVD exchange, S100B CSF concentrations were within the normal range in all patients (1.48 ± 0.37 μg/L), while NSE CSF concentrations were normal in four of five patients (6.51 ± 2.98 μg/L). Following EVD exchange, S100B and NSE CSF levels peaked significantly at 3 h after insertion of the new drain (S100B 39.02 ± 9.17 μg/L; NSE 54.80 ± 43.34 μg/L). S100B serum levels were slightly increased 6 to 24 h after EVD exchange. Beta-Trace concentrations in the CSF were not altered by EVD insertion. Our data demonstrate that EVD insertion results in a distinct increase of S100B and NSE concentrations in the CSF. Thus, the tampering of brain-derived protein concentrations in the CSF by diagnostic or therapeutic procedures has to be considered in the interpretation of neuromarker levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390981     DOI: 10.1089/neu.2012.2621

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  7 in total

Review 1.  Proteomics: in pursuit of effective traumatic brain injury therapeutics.

Authors:  Pavel N Lizhnyak; Andrew K Ottens
Journal:  Expert Rev Proteomics       Date:  2015-02       Impact factor: 3.940

2.  Elevated Serum Levels of NSE and S-100β Correlate with Increased Risk of Acute Cerebral Infarction in Asian Populations.

Authors:  Ke Li; Jianjun Jia; ZhenFu Wang; ShanChun Zhang
Journal:  Med Sci Monit       Date:  2015-06-30

Review 3.  Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids.

Authors:  Harel Adrian; Kvist Mårten; Nuutinen Salla; Välimaa Lasse
Journal:  eNeuro       Date:  2016-12-21

Review 4.  Brain Monitoring in Critically Neurologically Impaired Patients.

Authors:  Salazar Jones; Gary Schwartzbauer; Xiaofeng Jia
Journal:  Int J Mol Sci       Date:  2016-12-27       Impact factor: 5.923

5.  Clinical significance of changes in IL-6, CRP and S100in serum and NO in cerebrospinal fluid insubarachnoid hemorrhage and prognosis.

Authors:  Wensheng Zhang; Leitao Sun; Lixin Ma; Zefu Li
Journal:  Exp Ther Med       Date:  2018-05-29       Impact factor: 2.447

6.  Ventriculoperitoneal shunt is associated with increased cerebrospinal fluid protein level in HIV-infected cryptococcal meningitis patients.

Authors:  Ran Tao; Lijun Xu; Yongzheng Guo; Xiaoke Xu; Jiesheng Zheng; Biao Zhu
Journal:  BMC Infect Dis       Date:  2022-03-26       Impact factor: 3.090

7.  Metabolic syndrome and its components with neuron-specific enolase: a cross-sectional study in large health check-up population in China.

Authors:  Shu-Yi Wang; Xiao-Juan Zha; Xin-Ying Zhu; Wen-Bo Li; Jun Ma; Ze-Wei Wu; Huan Wu; Ming-Fei Jiang; Yu-Feng Wen
Journal:  BMJ Open       Date:  2018-04-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.